Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
Chemotherapy Statistics | Success Rate & Cost
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Frontiers | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: A meta‐analysis of randomized controlled trials - Wang - 2020 - The Breast Journal - Wiley Online Library
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer
PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial | npj Breast Cancer
Frontiers | Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
